# US 2012/0269763 A1 · Compositions and methods for reducing the risk of preterm labor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269763 A1
- Document ID: US20120269763A1
- Status: Published application
- Kind: A1
- Application number: 13/458,823
- Filed: 2012-04-27
- Published: 2012-10-25
- Earliest claimed: 2003-10-24
- Assignees: Nora Therapeutics, Inc.
- Inventors: Darryl Carter
- Web page: https://patentgrep.com/patent/US20120269763A1

## CPC

- G01N 33/689: {related to pregnancy or the gonads}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/12: Antihypertensives
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides compositions, kits and methods for the prevention of spontaneous abortion or implantation failure during assisted reproduction. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent spontaneous abortion or implantation failure of an embryo. The present invention also provides compositions, kits and methods for the treatment or prevention of preeclampsia and preterm labor.

## Claims

### Claim at position 1

-26. (canceled)

### Claim 27

A method for reducing the risk of preterm labor, comprising administering to a human female an effective amount of a granulocyte colony stimulating factor (G-CSF), wherein the G-CSF is administered at a dose ranging from 1 to 100 mcg (micrograms)/kg/day.

### Claim 28 (depends on 27)

The method of claim 27 wherein the G-CSF is administered at a dose ranging from 1 mcg/kg/day to 20 mcg/kg/day.

### Claim 29 (depends on 27)

The method of claim 27 wherein the G-CSF is administered at a dose ranging from 1 mcg/kg/day to 10 mcg/kg/day.

### Claim 30 (depends on 27)

The method of claim 27 wherein the G-CSF is filgrastim or pegfilgrastim.

### Claim 31 (depends on 27)

The method of claim 27 wherein the G-CSF is administered in the second trimester of pregnancy, third trimester of pregnancy, or both.

### Claim 32 (depends on 27)

The method of claim 27 wherein the G-CSF is administered before the second or third trimester of pregnancy.

### Claim 33 (depends on 27)

The method of claim 27 wherein the G-CSF is administered through the end of pregnancy.

### Claim 34 (depends on 27)

The method of claim 27 wherein the G-CSF is administered for the duration of pregnancy.

### Claim 35 (depends on 27)

The method of claim 27 wherein the G-CSF is administered daily for one to thirty-five consecutive days.

### Claim 36 (depends on 27)

The method of claim 27 wherein the G-CSF is administered for four, three, two or one week.

### Claim 37 (depends on 27)

The method of claim 27 wherein the G-CSF is administered for five, four, three, two or one day.

### Claim 38 (depends on 27)

The method of claim 27 wherein the G-CSF is administered to a human female having a high Th1 immune response, a low Th2 immune response, or both.

### Claim 39 (depends on 38)

The method of claim 38 wherein the G-CSF is administered until the human female recipient has a normal Th1 response, a normal Th2 response, or both.

### Claim 40 (depends on 27)

The method of claim 27 wherein the G-CSF is administered about one day, about two days, about three days, about four days, about one week, about two weeks and up to about eight weeks, following signs of preterm labor.

### Claim 41 (depends on 27)

The method of claim 27 wherein the G-CSF is administered parenterally, enterally, subcutaneously, percutaneously, transdermally, intradermally, intravenously, topically, by inhalation, or by implantation.

### Claim 42 (depends on 27)

The method of claim 27 wherein the G-CSF is administered with another active agent.

### Claim 43 (depends on 42)

The method of claim 42 wherein the other active agent is an immunosuppressive agent or an anti-inflammatory agent.

### Claim 44 (depends on 42)

The method of claim 42 wherein the other active compound is vitamin D or aspirin.

### Claim 45 (depends on 42)

The method of claim 42 wherein the other active compound is heparin, intravenous immunoglobulin (IVIG) or progesterone.

### Claim 46 (depends on 27)

The method of claim 27 wherein the G-CSF is formulated as a composition comprising a pharmaceutically acceptable carrier or diluent.

### Claim 47 (depends on 27)

The method of claim 27 wherein the G-CSF is formulated for extended or prolonged release.

### Claim 48 (depends on 27)

The method of claim 27 wherein the human female is in the second or third trimester of pregnancy.

### Claim 49 (depends on 27)

The method of claim 27 wherein the human female was a recipient of an assisted reproduction procedure.

### Claim 50

A kit for preventing or reducing the risk of preterm labor in a human female, comprising an effective amount of G-CSF; and a label with instructions for using G-CSF at a dose ranging from 1 to 100 mcg (micrograms)/kg/day to prevent or reduce the risk of preterm labor.

### Claim 51 (depends on 50)

The kit of claim 50 wherein the G-CSF is formulated for administration parenterally, enterally, subcutaneously, intravenously, topically or by inhalation.

### Claim 52 (depends on 50)

The kit of claim 50 wherein the G-CSF is administered at a dose ranging from 1 mcg/kg/day to 20 mcg/kg/day.

### Claim 53 (depends on 50)

The kit of claim 50 wherein the G-CSF is administered at a dose ranging from 1 mcg/kg/day to 10 mcg/kg/day.

### Claim 54 (depends on 50)

The kit of claim 50 wherein the G-CSF is filgrastim or pegfilgrastim.
